PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Prothena Announces Research and Development Day and Webcast
DUBLIN, Ireland, Oct. 28, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of a broad range of diseases, today announced that it will
View HTML
Toggle Summary Prothena Announces Pricing of Public Offering of 5,910,000 Ordinary Shares
DUBLIN, Ireland, Oct. 3, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc. (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of a broad range of diseases, announced that it has priced an underwritten
View HTML
Toggle Summary Prothena Reports Second Quarter 2013 Financial Results
DUBLIN, Ireland, Aug. 12, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of a broad range of diseases, today reported financial results for the second
View HTML
Toggle Summary Prothena to Present at the Wedbush Securities Life Sciences Management Access Conference in New York
DUBLIN, Ireland, Aug. 7, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc. (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of a broad range of diseases, announced that Gene Kinney, PhD, the Company's
View HTML
Toggle Summary Prothena Welcomes New Director to Its Board
DUBLIN, Ireland, July 22, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of a broad range of diseases, today announced the appointment of Dennis J.
View HTML
Toggle Summary Prothena to Present at the Eighth Annual JMP Securities Healthcare Conference in New York
DUBLIN, Ireland, July 1, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc. (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of a broad range of diseases, announced that Dale Schenk, PhD, the Company's
View HTML
Toggle Summary Prothena Shares to Be Added to Russell Global Index
DUBLIN, Ireland, June 17, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of a broad range of diseases, announced that the trading of its ordinary shares
View HTML
Toggle Summary Prothena to Present at the Jefferies 2013 Global Healthcare Conference in New York
DUBLIN, Ireland, May 29, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc. (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of a broad range of diseases, announced that Dale Schenk, PhD, the Company's
View HTML
Toggle Summary Prothena Reports First Quarter Financial Results
Phase 1 Clinical Trial Initiated in April for NEOD001 in AL Amyloidosis Patients
View HTML
Toggle Summary First Patient Dosed in Phase I Study of Prothena's Therapeutic Antibody for Treatment of AL Amyloidosis
NEOD001 Enters Clinic With Orphan Designation and Potential to Meet Significant Unmet Need
View HTML
Toggle Summary Prothena Reports Fourth Quarter and Full Year 2012 Financial Results and Provides Research and Development Update
Company Advances Pipeline With Strong Capital Position Following 2012 Spin-Off NEOD001 to Enter Clinic in Early 2013 DUBLIN, Ireland, March 28, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a biotechnology company focused on the discovery and development of novel antibodies for
View HTML
Toggle Summary Prothena Announces Appointments of Chief Medical Officer and Chief Financial Officer
DUBLIN, Ireland, March 25, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of a broad range of diseases, today announced that two senior executives have joined the
View HTML
Toggle Summary Prothena to Report Fourth Quarter and Full Year 2012 Financial Results and Host Webcast and Conference Call on March 28, 2013
DUBLIN, Ireland, March 21, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of a broad range of diseases, today announced that it will report its fourth quarter and full
View HTML
Toggle Summary Prothena Announces Appointment of Biotech Pioneer to Board of Directors
DUBLIN, Ireland, March 19, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq: PRTA ), a biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of a broad range of diseases, today announced the appointment of Christopher S.
View HTML
Toggle Summary Prothena Achieves Orphan Drug Status in EU for Lead Program NEOD001
Potential Treatment for Systemic Amyloidoses Also Has US Designation
View HTML